SIGA Technologies delivers smallpox antiviral to U.S. Strategic National Stockpile
SIGA delivered the first in a series of deliveries of Arestvyr as part of its contract with the Biomedical Advanced Research and Development Authority. BARDA provides a systematic approach to developing and purchasing vaccines, drugs, therapies and diagnostic tools for public health emergencies. The contract calls for two million courses of Arestvyr in total, and the first delivery included approximately 190,000 courses of the drug.
"The men and women of SIGA are proud of their longstanding partnership with BARDA, taking this important step forward in protecting our fellow citizens against the threat of bioterrorism," Eric Rose, the chairman and CEO of SIGA, said. "This first commercial delivery marks a major milestone in SIGA's transformation from a research company to a commercial biopharmaceutical enterprise. While SIGA continues to research and develop pharmaceutical agents to fight other lethal pathogens, and concurrently seeks approval and licensing of Arestvyr from the U.S. Food and Drug Administration, this first delivery of Arestvyr to the stockpile is evidence of our ability to oversee the manufacture and delivery of large quantities of high-quality pharmaceutical product."
SIGA will receive payment through the BARDA contract after delivering 500,000 Arestvyr courses. Arestvyr, also known as Tecovirimat, is one of the first novel drugs to be developed, procured and delivered to the stockpile under Project BioShield.
"(The delivery) gives us great confidence in SIGA's capabilities and aspirations, and moves us well down the path to generating substantial contractual payments from BARDA later this year and beyond," Rose said.
Arestvyr is an investigational new drug not yet approved or licensed as safe and effective by the U.S. Food and Drug Administration.